LUNA: This trial is assessing how safe and well-tolerated a new drug (called MGC026) is in people with solid cancers that are locally advanced, inoperable, metastatic, relapsed or refractory.A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors

Exclusion

• Any underlying medical or psychiatric condition impairing participant's ability to receive, tolerate, or comply with the planned treatment or study procedures.
• Another cancer that required treatment within the past 2 years, with the exception of those with low risk of cancer spreading or death such as adequately treated non melanomatous skin cancer, localized prostate cancer (Gleason Score < 6), or carcinoma in situ.
• Patients with history of prior central nervous system (CNS) metastasis must have been treated, be asymptomatic, and not have concurrent treatment for CNS disease, progression of CNS metastases on magnetic resonance imaging, computed tomography or positron emission tomography, or history of leptomeningeal disease or cord compression at the time of enrollment.
• Treatment with surgery, systemic cancer therapy, immunotherapy, chimeric antigen receptor-T therapy, or anti-hormonal within protocol specified intervals.
• Prior autologous or allogeneic stem cell or solid organ transplant.
• Clinically significant cardiovascular, pulmonary, or gastrointestinal disorders.
• Active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 1 week of first study drug administration.
• Known history of hepatitis B or C infection or known positive test for hepatitis B surface antigen or core antigen, or hepatitis C polymerase chain reaction.
• Known positive testing for human immunodeficiency virus or history of acquired immune deficiency syndrome.
• History of primary immunodeficiency.
• Major trauma or major surgery within 4 weeks of first study drug administration.
• Known hypersensitivity to recombinant proteins.